- Home
- TRU vs ARWR Comparison
TRU vs ARWR Comparison
Compare TRU & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TRU | ARWR |
|---|---|---|
| Founded | 1968 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2B | 12.4B |
| IPO Year | 2013 | 2009 |
Fundamental Metrics
Financial Performance| Metric | TRU | ARWR |
|---|---|---|
| Price | $65.43 | $62.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 14 |
| Target Price | $92.24 | ★ $107.23 |
| AVG Volume (30 Days) | ★ 2.2M | 2.0M |
| Earning Date | 10-27-2026 | 11-24-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | 60.00 | ★ 99.80 |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $4,576,300,000.00 | $16,142,321.00 |
| Revenue This Year | $12.88 | N/A |
| Revenue Next Year | $7.72 | N/A |
| P/E Ratio | $31.66 | ★ N/A |
| Revenue Growth | ★ 9.38 | N/A |
| 52 Week Low | $60.96 | $34.61 |
| 52 Week High | $89.12 | $95.49 |
Technical Indicators
Market Signals| Indicator | TRU | ARWR |
|---|---|---|
| Relative Strength Index (RSI) | 37.37 | 32.23 |
| Support Level | $63.90 | $60.87 |
| Resistance Level | $74.19 | $66.37 |
| Average True Range (ATR) | 2.43 | 2.41 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 36.81 | 25.44 |
Price Performance
Historical ComparisonAbout TRU TransUnion
TransUnion, along with Equifax and Experian, is one of the three leading credit bureaus in the United States, providing the consumer information that is the basis for granting credit. The company also provides fraud detection, marketing, and analytical services. TransUnion operates in over 30 countries. About 20%-25% of its revenue comes from international markets.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.